Benefit-risk balance of hormone replacement therapy: Cancers and mortality. Postmenopausal women management- CNGOF and GEMVi clinical practice guidelines

被引：2

作者：

Poudou, C. ^{[1
]}

Baffet, H. ^{[2
,3
]}

Nadeau, C. ^{[1
]}

Rolland, A-L ^{[2
,3
]}

Catteau-Jonard, S. ^{[2
,4
]}

Robin, G. ^{[2
,4
]}

机构：

[1] CHU Poitiers, Serv Gynecol Obstet & Med Reprod, 2 Rue Miletrie, F-86021 Poitiers, France

[2] CHU Lille, Serv Gynecol Med Orthogenie & Sexol, Hop Jeanne de Flandre, Ave Eugene Avinee, F-59073 Lille, France

[3] CHU Lille, Serv Assistance Med Procreat & Preservat Fertilit, Ave Eugene Avinee, F-59037 Lille, France

[4] Univ Lille, Fac Med, 2 Ave Eugene Avinee, F-59120 Loos, France

来源：

GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE | 2021年 / 49卷 / 05期

关键词：

Hormone replacement therapy (HRT); Breast cancer; Colorectal cancer; Endometrial cancer; Ovarian cancer; Mortality; ESTROGEN PLUS PROGESTIN; ENDOMETRIAL CANCER; OVARIAN-CANCER; REPRODUCTIVE FACTORS; ESOPHAGEAL CANCER; COLORECTAL-CANCER; BREAST-CANCER; HEALTH; COHORT; INTERVENTION;

D O I：

10.1016/j.gofs.2021.03.031

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

The use of hormone replacement therapy (HRT) for menopausal women has been the subject of much controversy in recent years, particularly concerning the carcinologic risks. The purpose of this review is to evaluate the impact of the use of HRT on the risk of gynecological but also extra-gynecological cancers. The effect of the type and the duration of use of HRT in menopausal women will also be discussed. The beneficial impact of HRT on overall mortality is also an element that will be discussed and must be taken into account when evaluating the benefit-risk balance of HRT for menopausal women. (c) 2021 Elsevier Masson SAS. All rights reserved.

引用

页码：462 / 473

页数：12

共 27 条

[21] Use of NTx levels in the clinical management of hormone replacement therapy in early postmenopausal women.
Bell, N
Clark, G
Drinkwater, B
English, S
Johnston, C
Notelovitz, M
Rosen, C
Mallinak, N
Cain, D
Flessland, K
Chesnut, C
JOURNAL OF BONE AND MINERAL RESEARCH, 1996, 11 : P262 - P262
[22] Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: A debated clinical issue
Gadducci, Angiolo
Biglia, Nicoletta
Cosio, Stefania
Sismondi, Piero
Genazzani, Andrea Riccardo
GYNECOLOGICAL ENDOCRINOLOGY, 2009, 25 (12) : 807 - 815
[23] The Impact of Hormone Replacement Therapy on the Risk of Heart Failure in Postmenopausal Women: A Meta-Analysis of Clinical and Observational Studies
Arayici, Mehmet Emin
Kilic, Mustafa Eray
Yilmaz, Mehmet Birhan
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 (10)
[24] Clinical practice guidelines for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer
Pritchard, KI
Khan, H
Levine, M
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2002, 166 (08) : 1017 - +
[25] Effects of hormone replacement therapy on cognitive aging and dementia risk in postmenopausal women: a review of ongoing large-scale, long-term clinical trials
Zec, RF
Trivedi, MA
CLIMACTERIC, 2002, 5 (02) : 122 - 134
[26] Withholding of Hormone Replacement Therapy Prior to Total Joint Arthroplasty Surgery to Reduce the Risk of Postoperative Thromboembolic Events: Is It Justified?dA Systematic Review of Clinical Practice Guidelines
Abouharb, Alexander L. Z.
Mehta, Sachit
Rathnayake, Hasithe
Pandit, Hemant
JOURNAL OF ARTHROPLASTY, 2024, 39 (02): : 541 - 548.e24
[27] Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement This practice statement has been endorsed by The North American Menopause Society
Sinno, A. K.
Pinkerton, J.
Febbraro, T.
Jones, N.
Khanna, N.
Temkin, S.
Iglesias, D.
Pothuri, B.
GYNECOLOGIC ONCOLOGY, 2020, 157 (02) : 303 - 306

← 1 2 3 →